Skip to main content
Terug
Watch Compare

Propanc Biopharma, Inc.

Datakwaliteit: 83%
PPCB
Nasdaq Manufacturing Chemicals
€ 0,10
▼ € 0,03 (-20,63%)
Marktkapitalisatie: 2,10 M
Prijs
€ 0,10
Marktkapitalisatie
2,10 M
Dagbereik
€ 0,10 — € 0,12
52-Weeksbereik
€ 0,10 — € 11,00
Volume
1.925.120
Openen € 0,12
50D / 200D Gem.
€ 0,18
44,01% below
50D / 200D Gem.
€ 2,01
95,03% below

Quick Summary

Belangrijkste Punten

Debt/Equity of 0,01 — conservative balance sheet
Negative free cash flow of -3,11 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-532,52%
Onder sectorgemiddelde (-53,47%)
ROIC-397,29%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
0,01
Onder sectorgemiddelde (0,31)
Current Ratio2,13
Interest Coverage-90,02

Waardering

PE (TTM)
-0,03
Boven sectorgemiddelde (-1,47)
P/B Ratio0,20
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E 0,0 -1,5
P/B 0,2 1,6
ROE % -532,5 -53,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E 0,0 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -66,07 M
ROE -532,52% ROA -399,36%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -3,11 M
ROIC -397,29% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,01 Current Ratio 2,13
Interest Coverage -90,02 Asset Turnover N/A
Working Capital 4,08 M Tangible Book Value 10,45 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,03 Forward P/E N/A
P/B Ratio 0,20 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -148,03%
Market Cap 2,10 M Enterprise Value 2,15 M
Per Share
EPS (Diluted TTM) 52,10 Revenue / Share N/A
FCF / Share -0,15 OCF / Share -0,15
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 4,70%
SBC-Adj. FCF -10,11 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -58,92 M -1,82 M -2,66 M -2,66 M -2,42 M
EPS (Diluted) -14,85 -0,02 -1,80 — —
Gross Profit — — — — —
Operating Income -57,28 M -1,54 M -1,78 M -1,99 M -1,81 M
EBITDA — — — — —
R&D Expenses 223.721,0 248.102,0 247.919,0 256.052,0 230.956,0
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 563.757,0 665.841,0 532.821,0 568.798,0 449.457,0
Income Tax -129.132,0 -129.132,0 -129.841,0 -54.977,0 -113.415,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 19,63 M 72.365,0 60.328,0 81.651,0 13.101,0
Total Liabilities 5,73 M 3,85 M 3,18 M 3,11 M 3,08 M
Shareholders' Equity 13,91 M -3,78 M -3,12 M -3,02 M -3,07 M
Total Debt 537.921,0 399.325,0 390.539,0 984.260,0 624.583,0
Cash & Equivalents — — — 4.067,0 2.255,0
Current Assets 8,35 M 25.441,0 19.039,0 15.030,0 6.596,0
Current Liabilities 5,58 M 3,79 M 3,16 M 3,06 M 3,08 M